bedside procedures –the reporting dilemmastxhfma.org/wp-content/.../2017/07/...2017-6-26-17.pdf1...
TRANSCRIPT
1
RevenueRoundtableJune2017
BedsideProcedures– TheReportingDilemmaManyhospitalsstrugglewiththeconceptofwhethercharges
shouldorshouldnotbeseparatelyreported.
ImplementingthenewcodesforJulySeveralancillarydepartmentsareimpactedbythe
July2017OPPSupdates.Theimplementationdateisjust
aroundthecorner.
MarkYourEducationalCalendarTheyearseemstobeflyingbyandbeforeyouknowit….
itwillbetimetoupdatethechargemasterfor2018.
HCS’educationaldatesarelocatedonPage10.
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved
2
Pg #Content
3 Bedside ProcedureCharges– TheReportingDilemma
A lotofeducationandplanningisinvolvedwhen/ifafacilitydecidesto
capturebedsideprocedures,particularlywhennoadditionalnet
reimbursementisgained.Thenwhydoit?
6 NewCodeUpdatesforJuly2017The new laboratory,bloodbank,surgery, clinicandpharmacycodesthat
mustbeimplementedinafewdaysisreviewed.Isthechargemasterready
andstaffprepared?
10HCSEducationalSchedule Markyoureducationalcalendarnowforthe new2018CPTandHCPCS
ChargemasterSeminar.Reserveyourspotnow….attendeesareregistering
now!
11AboutHCSandtheRevenue RoundtableNewsletter
LearnaboutHCSHealthCareConsultingSolutionsandthisbi-monthlyfree
newsletteraswellasupcomingseminardatesinyourarea!
RevenueRoundtableJune2017
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved 3
Time seems to fly faster and faster and its
hard to believe we are discussing mid-year
coding changes already. Before you turn
around we will be reviewing the 2018 code
updates. It’s time now to consider the
educational needs of staff for the new coding
rules, payment regulations and the numerous
anticipated new, revised and deleted CPT and
HCPCS codes by dedicating time in busy
schedules to attend one of HCS’ 2018
Chargemaster seminars. Please see the
educational time schedule on page 10.
Inpatient coding professionals are used to MS-
DRG systems where all of the diagnoses and
procedures map to a single MS-DRG. If the
hospital receives only one payment for the
entire hospital stay, many department
directors and Chief Financial Officers often do
not place emphasis on reporting charges for
bedside procedures. In addition, a common
concern for hospital providers is that if they
charge a bedside procedure for an inpatient,
they are “double dipping”—that is, they are
charging twice because everything is included
in the room rate. When departments are
questioned about what services have been
included in the current room rate, no one
seems to know. It has been the perception
that “all” nursing services provided are part of
the room and board.
By definition, a bedside procedure is any
procedure that is performed at the patient’s
bedside. It really is that simple. Some of the
most common examples of bedside
procedures are:
• ThoracentesisorParacentesis
• Lumbarpuncture
• Peripherallyinsertedcentral
catheter(PICC)lineinsertion
• Insertionofaurinarycatheter
• Cardioversion
• Incisionanddrainageprocedures
• Negativepressurewoundtherapy
• Centrallinedeclot procedures
• Pleurodesis
• Arthrocentesisandjointinjections
• Echocardiograms
• Biopsies(e.g.,bonemarrowbiopsy)
• Endotrachealintubation
• Bloodtransfusions
Why should hospitals focus on charging
bedside procedures? One of the major
reasons is that all patients spending the night
in a hospital bed are not inpatients.
Outpatient observation patient volumes have
been on the rise even with the
implementation of the two-midnight rule, and
capturing charges for all injections, infusions
as well as any procedures performed is
imperative when submitting these claims for
payment. Missed charges definitely count
when it comes to receiving maximum
reimbursement for observation services.
Should we charge for these services only for
observation patients and ignore these
services when the patient is an inpatient?
Doesn’t seem plausible….particularly when
providers should be charging all patients
consistently.
When a bedside procedure is performed, a
sterile field is prepared, instrumentation
available, required supplies ready, and nursing
staff in attendance to assist the physician.
There is virtually no difference in a procedure
that is performed at bedside versus the same
procedure that is performed in a treatment
room or operating room.
BedsideProcedures– TheDilemma
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved 4
Charging for procedures performed at the
inpatient bedside can improve cost data
captured for each individual patient which
can dramatically provide more specific cost
information to make informed operational
decisions. It can also increase transparency
as data ultimately reflects cost of services
provided related to the MS-DRG. Clinical
nursing departments may become more
focused on charge capture if they get credit
for these services, ultimately helping to
support added staff or new equipment
requests.
These procedures would be generated for
both inpatients as well as any patient in
observation/outpatient status. As a general
rule, any procedure performed by a
physician, PA, NP, resident or intern, or any
other health care professional qualified to
perform the surgical procedure, can be billed
to capture the technical component for
these procedures.
When an ancillary department is present and
assists the physician, this ancillary
department should generate the charge for
the procedure. For example, if an ultrasound-
guided thoracentesis is performed and
radiology department brings the equipment
and operates the ultrasound machine while
the physician performs the procedure,
radiology will capture the procedure charge.
If endoscopy or respiratory therapy is
present and assists with a bedside
bronchoscopy, the ancillary department
present will undoubtedly charge for the
procedure. It is those instances when no
other ancillary department is present and
nursing assists the physician that the charge
should be captured by the specific nursing
area. The cost of nursing resources utilized
when providing bedside procedures is no less
important than the cost of resources to
perform the same procedures in a hospital
department, even though the performance
of the procedure does not differ.
Approximately eighty percent (80%) of
procedures performed at the patient’s
bedside would require a consent to be
signed by the patient and/or representative
which could be one helpful indication to
nursing staff that a charge should be
reported when a signed consent is obtained.
Nurses may actually perform other billable
procedures, such as insertion of a urinary
catheter, declot a central/peripheral vein or
perform a bladder scan.
Documentation is key to ensure the medical
record contains the physician’s order and
procedure note or supportive
documentation by the professional who
performed the procedure.
Once a facility decides to pursue charges for
the above discussed bedside procedures, it is
suggested a room and board policy be
developed should the facility not currently
have such a policy. Are all of the services
currently provided to inpatients truly
included in the cost, and in turn, included in
the charge for the room rate? Medicare
does provide the following guidance:
Inpatient routine services in a hospital orskilled nursing facility generally are thoseservices included in by the provider in a dailyservice charge--sometimes referred to as the"room and board“ charge. Routine services
BedsideProcedures– Continued
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved 5
are composed of two board components;(l) general routine services, and (2) specialcare units (SCU's), including coronary careunits (CCU's) and intensive care Units(ICU's). Included in routine services are theregular room, dietary and nursing services,minor medical and surgical supplies, medicalsocial services, psychiatric social services,and the use of certain equipment andfacilities for which a separate charge is notcustomarily made.
Reference: Provider ReimbursementManual, 2202.6
After making the decision to report bedside
procedures, the process should include
representatives from the chargemaster
team, finance, third-party contracting,
revenue integrity, all clinical departments
impacted as well as those responsible for
charge capture or charge entry. Answers to
some of these questions is important, and
can include some of the following: 1) When
will the charges be captured? 2) Who will be
responsible for the charge capture? 3) If
using a manual charge ticket, how will the
completion of the ticket take place and by
whom? 4) Can the electronic medical record
be utilized to charge upon completion of
documentation?
Facilities need to keep the charge capture
process simple to not be burdensome and
time-consuming but consistent and
accurate. The skills and expertise of IT may
be extremely helpful and an IT team
member should be included in the planning
stages and processes.
The successful implementation of a charge
capture process for bedside procedures will
be helpful for observation/outpatients
patients. Many times, inpatients and
outpatients are in the same nursing unit, are
taken care of by the same nursing staff,
receiving many of the same services.
Observation patients often receive services
and procedures such as drug administration,
lumbar punctures, and foley catheter
insertions in addition to observation. While
outpatient coders routinely report the CPT
codes for these procedures, the charges are
often missed, making it a challenge for the
surgical CPT code to link with the charge line
and report on the UB-04.
The Medicare Provider ReimbursementManual states in Section 2202.4 that
charges refer to the regular rates
established by the provider. It continues on
by stating, "Charges should be related
consistently to the cost of the services and
uniformly applied to all patients whether
inpatient or outpatient." Effective February
2014, Medicare issued Transmittal 3106
which contained some additional guidance:
Inpatient routine services in a hospitalgenerally are those services included by theprovider in a daily service charge--sometimes referred to as the "Room andBoard" charge. They include the regularroom, dietary and nursing services, minormedical and surgical supplies, medical socialservices, psychiatric social services, and theuse of certain equipment and facilities forwhich a separate charge is not customarilymade to Medicare Part A. Many nursingservices provided by the floor nurse (such as
BedsideProcedures– Continued
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved 6
IV infusions and injections, bloodadministration, and nebulizer treatments,etc.) may or may not have a separate chargeestablished depending upon theclassification of an item or service as routineor ancillary among providers of the sameclass in the same State. Some provider’scustomary charging practice has establishedseparate charges for these services followingthe PRM–1 instructions, however, in orderfor a provider’s customary charging practiceto be recognized it must be consistentlyfollowed for all patients and this must notresult in an inequitable apportionment ofcost to the program. If the PRM–1instructions have not been followed, aprovider cannot bill these services asseparate charges. Additionally, it isimportant that the charges for servicerendered and documentation meet thedefinition of the HCPCS in order toseparately bill.
https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R3106CP.pdf
As noted, Transmittal 3106 includes
additional clarification concerning what
nursing services may or may not be
separately generated such as IV infusions
and injections, blood administration, and
nebulizer treatments, depending on
whether they are classified as routine or
ancillary among providers of the same class
in the same state.
Unfortunately, hospitals don't often know
what other hospitals in their state do.
Hospitals can try reaching out to their state
hospital association to see if the association
can provide that information. It has been
reported by a hospital in Texas that recently
a third-party payer had denied charges for
injections and infusions reported on an
inpatient claim, TOB 0111. The reason for
the denial….the payer quoted Transmittal
3106.
Should the facility elect to charge for all
bedside procedures, it becomes imperative
to review any claim/charge denial with
contract management. When contracts are
renegotiated the bedside procedure
payment policy should be a point of
discussion.
Several new CPT and HCPCS codes have
been made available through the issuance
of Transmittal 3783, July 2017 Update of the
Hospital Outpatient Prospective Payment
System (OPPS). Some of the significant
coding updates are discussed below:
Pharmacy will have four new vaccine
products to report using the following new
CPT codes:
CPT 90587 Dengue vaccine, quadrivalent,live, 3 dose schedule, for subcutaneous use(SI E1)
CPT 90620 Meningococcal recombinantprotein and outer membrane vesicle vaccine,serogroup B (MenB-4C), 2 dose schedule, forintramuscular use (SI M)
NewCodeUpdatesforJuly2017
BedsideProcedures– Continued
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved 7
CPT 90621 Meningococcal recombinantlipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscularuse (SI M)
CPT 90651 Human Papillomavirus vaccinetypes 6, 11, 16, 18, 31, 33, 45, 52, 58,nonavalent (9vHPV), 2 or 3 dose schedule, forintramuscular use (SI M)
Issued by the AMA in January, 2017, CMS has
now assigned status indicators and
incorporated these four new vaccines into the
Hospital Outpatient Prospective Payment
System. While the status indicators of E1 (Not
covered by any Medicare outpatient benefit
category) and M (Items and Services Not
Billable to the MAC) have been assigned to
these vaccine products, providers may report
these specific vaccine products July 1, 2017.
These new CPT codes will be included in the
2018 CPT codebook.
An existing vaccine CPT code 90682, Influenzavirus vaccine, quadrivalent (riv4), derived fromrecombinant dna, hemagglutinin (ha) proteinonly, preservative and antibiotic free,
for intramuscular use, has changed status
indicators from E1 to L. Transmittal 3783
states CPT 90682 is approved for use in the
2017-2018 flu season. Because this code is
not payable until the start of the 2017 flu
season, the status indicator will be
retroactively corrected from 1/1/17 through
6/30/17 to E1. Effective 7/1/17 the status
indicator be updated to L.
Two new drugs will be eligible for reporting
July 1, 2017 which has been granted pass-
through status with the assignment of status
indicator G. These new codes are:
HCPCS C9489 Injection, nusinersen, 0.1 mg.Nusinersen (INN), marketed as Spinraza, is a
biologic drug used in treating spinal muscular
atrophy (SMA), a rare neuromuscular disorder.
HCPCS C9490 Injection, bezlotoxumab, 10 mg.Bezlotoxumab is a human monoclonal
antibody designed for the prevention of
recurrence of Clostridium difficile infections.
Both C9489 and C9490 will be reportable
using revenue code 0636.
Other pharmaceutical HCPCS codes
introduced July 1 are listed below:
HCPCS Q9984 Levonorgestrel-releasingintrauterine contraceptive system (Kyleena),19.5 mg (SI E1). Kyleena is a hormone-
releasing IUD that prevents pregnancy for up
to 5 years
HCPCS Q9985 Injection, hydroxyprogesteronecaproate, not otherwise specified, 10 mg (SI
N). CMS introduced a miscellaneous or “not
otherwise specified, HCPCS for this steroidal
progastrin product. There are several
different brand names for this product and
pharmacy staff will be helpful to identify all
drug products which may be eligible for
reporting using Q9985.
HCPCS Q9986 Injection, hydroxyprogesteronecaproate (Makena), 10 mg (SI K). CMS
changed the status indicator of J1725,
Injection, hydroxyprogesterone caproate, 1mg, from K to E1, so facilities will be unable to
report J1725 to Medicare after July 1, 2017. A
new HCPCS code, Q9986 will be reportable
and payable with noted dosage change from
“per 1 mg” to “per 10 mg”.
NewCodeUpdates…(Cont’d)
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved 8
The last code change for drugs is the deletion
of C9487 replaced with HCPCS Q9989,
Ustekinumab, for Intravenous Injection, 1 mg.This code was introduced in April 2017 and is
an immunosuppressive recently approved by
the FDA for treatment of Crohn’s disease. The
brand name for this drug is Stelara.
The Blood Bank will undergo a change for July
1, 2017. Up to this point, all blood products
have been reported using HCPCS “P” codes.
HCPCS P9072, Platelets, pheresis, pathogenreduced or rapid bacterial tested, each unit,will change from status indicator R, Blood and
Blood Products, to E1, Not covered by any
Medicare outpatient benefit category. To
replace this blood product’s HCPCS code, CMS
created HCPCS Q9988, Platelets, pathogenreduced, each unit, containsing status
indicator R.
The FDA approved a plasma pathogen
reduction system for use in reducing the risk
of transfusion transmitted infections often
present in plasma from whole blood and/or
apheresis. This system exposes the specimen
to ultraviolet light and a chemical called
amotosalen. The specimen is purified to
remove the chemical and any remaining
byproducts. It can then be utilized for
transfusion purposes. Code Q9988 may also
be used for plasma subjected to rapid
bacterial testing. A new HCPCS Q9987,
Pathogen(s) test for platelets, was created to
report the specialized testing performed on
the pheresis platelet product.
Over 17 million patients receive in excess of
60 million units of individual blood
components annually in North America,
Europe and Asia, and each of these
components is at risk for bacterial
contamination. The biggest risk in the nation's
blood supply is no longer HIV or hepatitis C,
its bacterial contamination of platelets,
resulting in at least 20 deaths and hundreds of
adverse reactions in recent years, health
experts say. This can essentially mean that
as many as 12,000 bacterially contaminated
blood components may be transfused every
year representing the single greatest source
of fatalities attributable to infectious agents in
transfusion medicine today. In recognition of
this risk, the American Association of Blood
Banks implemented a standard requiring all of
its members implement methods to limit and
detect bacterial contamination in platelets.
Verax Biomedical has introduced a test called
Platelet PGD Test for the detection of
bacterial contamination in platelets. It is the
only test cleared by the FDA as a Safety
Measure for leukoreduced apheresis platelets
within 24 hours prior to transfusion. The
hospital may presently be performing the PGD
test (reporting using an unlisted CPT code)
and as of July 1, will be reporting the
pathogen testing on the platelet product
using Q9987. Usually this test will be
performed and reported one to two days prior
to the transfusion of the platelet product;
therefore, both Q9987 and Q9988 will rarely,
if ever, be reported on the same date of
service.
For 2017, in response to the Protecting Access
to Medicare Act of 2014 (PAMA), the AMA has
developed a new category of CPT codes,
known as Proprietary Laboratory Analysis
(PLA), which will be released on a quarterly
basis. These alphanumeric CPT codes will be
in a distinct chapter of the code book, located
NewCodeUpdates…(Cont’d)
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved 9
after the Pathology and Laboratory CPT code
book sections, and before the Medicine code
section. At the present time there are three
new codes that have been released, with
expected new codes to be released each
quarter.
Proprietary Laboratory Analyses codes
describe proprietary clinical laboratory
analyses and can be either provided by a
single (“sole-source”) laboratory or licensed
or marketed to multiple providing
laboratories (e.g., cleared or approved by the
Food and Drug Administration (FDA)).
The PLA CPT codes will easily be recognized as
they end in the letter U. There are three CPT
codes that were introduced February 1, 2017
and are listed below:
CPT 0001U – Red blood cell antigen typing,
DNA, human erythrocyte antigen gene
analysis of 35 antigens from 11 blood groups,
utilizing whole blood, common RBC alleles
reported
Proprietary Name and Clinical Laboratory or
Manufacturer: Precise Type HEA Test,Immucor, Inc.
CPT 0002U – Oncology (colorectal),
quantitative assessment of three urine
metabolites (ascorbic acid, succinic acid and
carnitine) by liquid chromatography with
tandem mass spectrometry (LC-MS/MS) using
multiple reaction monitoring acquisition,
algorithm reported as likelihood of
adenomatous polyps
Proprietary Name and Clinical Laboratory orManufacturer: PolypDX, Atlantic DiagnosticLaboratories, LLC, Metabolomic TechnologiesInc
CPT 0003U – Oncology (ovarian) biochemical
assays of five proteins (apolipoprotein A-1, CA
125 II, follicle stimulating hormone, human
epididymis protein 4, transferrin), utilizing
serum, algorithm reported as a likelihood
score
Proprietary Name and Clinical Laboratory orManufacturer: Overa (OVA1 NextGeneration), Aspira Labs, Inc., Vermillion, Inc.
Proprietary Laboratory Analyses (PLA) codes
describe proprietary clinical laboratory
analyses and can be either provided by a
single (“sole-source”) laboratory or licensed
or marketed to multiple providing
laboratories (e.g., cleared or approved by the
Food and Drug Administration (FDA). PLA CPT
codes are available to any clinical lab or
manufacturer that wants to specifically
identify their lab test. Applications are being
accepted as January 2017, approved on a
quarterly basis and implemented the
following quarter. These new codes can be
obtained by checking the following website,
amaproductupdates.org, with the new codes
included in the code book the following year.
It has been reported the AMA anticipates
approximately 500 applications to be
submitted initially, with the approval of the
above three mentioned CPT codes.
Two additional PLA CPT codes were
introduced May 1, 2017 which are displayed
below:
CPT 0004U Infectious disease (bacterial),
DNA, 27 resistance genes, PCR amplification
NewCodeUpdates…(Cont’d)
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved 10
and probe hybridization in microarray format
(molecular detection and identification of
AmpC, carbapenemase and ESBL coding
genes), bacterial culture colonies, report of
genes detected or not detected, per isolate
Proprietary Name and Clinical Laboratory orManufacturer: Gram-Negative BacterialResistance Gene PCR Panel, Mayo Clinic,Check-Points Health BV, Wageningen,Netherlands
CPT 0005U Oncology (prostate) gene
expression profile by real-time RT-PCR of 3
genes (ERG, PCA3, and SPDEF), urine,
algorithm reported as risk score
Proprietary Name and Clinical Laboratory orManufacturer: ExosomeDx Prostate(IntelliScore), Exosome Diagnostics, Inc.
2018 CPT and HCPCS Update Seminars: It isanticipated the 2018 CPT and HCPCS code
additions, revisions and deletions will greatly
impact not only the facility’s chargemaster
but also reimbursements and charge capture
processes. HCS will be conducting two
information-packed seminars that will focus
on updating the chargemaster. Attendees can
return home armed with the necessary
information to implement the new changes
and educate departmental staff.
This all day seminar will focus on all ancillary
departments impacted by the new coding
revisions as well as include problematic
charging and billing areas hospitals are
currently experiencing and provide some
added insight on other facility successes in
overcoming the ever-complex world of
chargemaster.
Monday, November 13, 2017 (Dallas, TX) atDFWWestin.
Tuesday, November 14, 2017 (San Antonio,TX at Marriott Northwest)
For more information, contact Jeff
Neustaedter, President of HCS HealthCare
Consulting Solutions.
Brochure and registration material will beemailed in mid/late August.
Revenue Roundtable NewsletterWelcome to the Revenue Roundtable
Newsletter. HCS HealthCare Consulting
Solutions would like to introduce you to this
bi-monthly newsletter, developed for the
healthcare professional working within a
variety of settings. The future newsletters will
feature industry experts who will discuss best
practices for a variety of topics plaguing
healthcare providers ultimately impacting the
facility’s bottom line.
Subscription is “free”. Comments and
questions are always welcomed. Recipients of
this newsletter are encouraged to share with
colleagues and co-workers. To submit
subscription requests, ask questions or
communicate directly with the “Revenue
Roundtable” newsletter editors, please e-
mail: [email protected]
NewCodeUpdates…(Cont’d) Seminars– MarkYourCalendar!!
Newsletter/AboutHCS
RevenueRoundtable/June2017HCSHealthCareConsultingSolutions- AllRightsReserved 11
Contributing Writers for June’s Newsletter:
GlendaJSchuler,RHIT,
CPC,COC
Glenda brings an extensive background in
chargemaster, billing, operations, ICD-10-CM/PCS, DRG
coding and hospital CPT-4 coding, and has over 30
years of healthcare industry experience and expertise
in all areas of health information, medical records,
utilization review, patient access and business
services. Additionally, she’s an expert in third party
reimbursement, electronic submission of claims,
billing and collections, and revenue cycle solutions.
Glenda is a nationally featured speaker for the
American Academy of Professional Coders (AAPC),
American Health Information Management
Association (AHIMA), VHA, various state hospital
associations and OptumInsight.
Glenda’s Contact Information is:
[email protected]; Ph: 702.638.2989
About HCSHealthCare Consulting Solutions (HCS) provides a
broad spectrum of services and solutions in revenue
cycle management, chargemaster, strategic pricing,
coding, documentation, reimbursement, billing,
compliance and education for hospitals and physician
practices. Now in its twenty-first year, HCS prides itself
on adding new services to better meet the ever-
expanding needs of the health care industry.
HCS specializes in assisting health care providers
become more efficient through increasing their
payment incentives and growth in a compliant
business environment. HealthCare Consulting
Solutions focuses on hospital and physician consulting
services that include:
• Inpatient (MS-DRGs), Outpatient (APCs) and
Physician Practice Due Diligence &
Compliance Risk Assessments including RAC,
CERT, ZPIC, MAC/Carrier and OIG target
areas;
• CAH and Rural Health Clinic Compliance
Audits and Education/Training; DMEPOS
Reviews, Operational Assessments and
Education/Training;
• IRF, IPF, SNF, HHA and Hospice Reviews;
• ChargemasterAssessmentswithTraining
andEducation;
• PharmacyandSupplyAssessments;
• PhysicianDocumentationandQuality
Training;
• HospitalandPhysicianComplianceAudits;
• RevenueCycle,BusinessOperations,and
ChargeCapture/LostChargeAssessments;
• Web-basedRegistrationSolutions;
• Educationalworkshops/conferences;
• StrategicPricing,CostandChargeAnalysis
andHospital/PhysicianProfiles;and,
• Hospital and physician
national/regional/local call center
HCS Seminars: Our seminar and
education/training division provides
chargemaster, coding, billing and compliance
educational programs for state hospital
associations, hospital systems, and National
Group Purchasing Organizations.
For more information, please contact:
HCSHEALTHCARECONSULTINGSOLUTIONSJeffNeustaedter,President
3965W.83rdStreet,#310
ShawneeMission,Kansas66208
Ph:800.659.6035
FAX800.376.9137
Cell816.309.8600
www.hcsglobal.net
Newsletter/AboutHCS…Continued